Advisor Partners LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.6% during the second quarter, Holdings Channel reports. The institutional investor owned 5,025 shares of the pharmaceutical company’s stock after buying an additional 860 shares during the period. Advisor Partners LLC’s holdings in Vertex Pharmaceuticals were worth $648,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the company. Guardian Life Insurance Co. of America boosted its stake in Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 6 shares in the last quarter. Elk Creek Partners LLC boosted its stake in Vertex Pharmaceuticals by 0.3% in the first quarter. Elk Creek Partners LLC now owns 3,120 shares of the pharmaceutical company’s stock worth $341,000 after buying an additional 10 shares in the last quarter. Sowell Financial Services LLC boosted its stake in Vertex Pharmaceuticals by 0.8% in the first quarter. Sowell Financial Services LLC now owns 2,762 shares of the pharmaceutical company’s stock worth $325,000 after buying an additional 23 shares in the last quarter. Capital Investment Advisory Services LLC boosted its stake in Vertex Pharmaceuticals by 0.4% in the first quarter. Capital Investment Advisory Services LLC now owns 6,463 shares of the pharmaceutical company’s stock worth $707,000 after buying an additional 25 shares in the last quarter. Finally, First Manhattan Co. boosted its stake in Vertex Pharmaceuticals by 1.3% in the first quarter. First Manhattan Co. now owns 2,356 shares of the pharmaceutical company’s stock worth $205,000 after buying an additional 31 shares in the last quarter. 93.13% of the stock is owned by institutional investors and hedge funds.

Shares of Vertex Pharmaceuticals Incorporated (VRTX) opened at 154.54 on Monday. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85. The company’s 50-day moving average is $137.73 and its 200 day moving average is $111.96. The stock has a market capitalization of $38.96 billion, a P/E ratio of 148.45 and a beta of 1.77.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.33. The business had revenue of $544.10 million for the quarter, compared to analysts’ expectations of $489.95 million. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The company’s quarterly revenue was up 26.1% on a year-over-year basis. During the same period last year, the company earned $0.24 earnings per share. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.59 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Advisor Partners LLC Increases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/07/advisor-partners-llc-increases-stake-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html.

A number of analysts have recently commented on the stock. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Sunday, April 30th. UBS AG restated a “buy” rating and set a $135.00 price target (up from $132.00) on shares of Vertex Pharmaceuticals in a research report on Friday, May 19th. Stifel Nicolaus boosted their price target on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Robert W. Baird restated an “outperform” rating and set a $171.00 price target (up from $136.00) on shares of Vertex Pharmaceuticals in a research report on Friday, July 21st. Finally, Cowen and Company restated a “market perform” rating and set a $105.00 price target on shares of Vertex Pharmaceuticals in a research report on Thursday, July 6th. Five analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $162.88.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 70,969 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $128.06, for a total transaction of $9,088,290.14. Following the transaction, the executive vice president now directly owns 145,061 shares of the company’s stock, valued at $18,576,511.66. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Paul M. Silva sold 2,577 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of $133.36, for a total transaction of $343,668.72. Following the transaction, the senior vice president now directly owns 22,648 shares in the company, valued at $3,020,337.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 745,503 shares of company stock worth $112,220,787. 1.80% of the stock is currently owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.